An observational study in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Active, not recruiting at 31 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Intergroupe Francophone du Myelome · Observational
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria.
This is a multicenter, prospective, observational study.
French adult patient relapsed and refractory multiple myeloma receving teclistamab
Exclusion Criteria:
overall response rate (ORR) of teclistamab according to IMWG criteria
ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.
Time frame: 6 months
overall response rate (ORR) of teclistamab according to IMWG criteria
ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.
Time frame: 24 months
Effectiveness of teclistamab
Progression Free Survival 1 and 2 (PFS)
Time frame: 24 months
Effectiveness of teclistamab
Overall survival (OS)
Time frame: 24 months
Effectiveness of teclistamab
Duration of overall response (DOR)
Time frame: 24 months
Effectiveness of teclistamab
Response rate (sCR, CR, VGPR, PR)
Time frame: 24 months
Effectiveness of teclistamab
Time to best response
Time frame: 24 months
Effectiveness of teclistamab
Time to next treatment (TTNT)
Time frame: 24 months
Effectiveness of teclistamab
Time to discontinuation (TTD)
Time frame: 24 months
Adverse events of interest
ICANS, CSR and infections
Time frame: 24 months
Conditions of use
Patients' profiles (demographics characteristics and medical history) \- Injection facilities and schedules during step-up dosing phase
Time frame: 1 month
Conditions of use
Patients' profiles (demographics characteristics and medical history) \- Injection facilities and schedules during follow up phase
Time frame: 24 months
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intergroupe Francophone du Myelome